Table 2. Characteristics of the patients; arm A: DG followed by erlotinib if progression, arm B: erlotinib followed by DG if progression.
| Arm A (n=48) | Arm B (n=51) | |
|---|---|---|
| Age, mean, (years) | 76.0±4.65 | 75.7±4.11 |
| Gender: male (%) | 29 (60.4) | 30 (58.8) |
| Weight loss >5% (%) | 19 (36.6) | 18 (36) |
| Smoker | ||
| Current (%) | 6 (12.8) | 8 (15.7) |
| Former (%) | 26 (54.2) | 25 (49) |
| Never smoker (%) | 15 (31) | 15 (29.4) |
| Unknown (%) | 1 (2) | 3 (5.9) |
| Performance status | ||
| 0 (%) | 22 (46.8) | 21 (41.2) |
| 1 (%) | 21 (44.7) | 28 (54.9) |
| 2 (%) | 4 (8.5) | 2 (3.9) |
| Stage | ||
| IIIB (%) | 6 (12.5) | 4 (7.8) |
| IV (%) | 42 (87.5) | 47 (92.2) |
| Histology | ||
| Squamous cell (%) | 11 (22.9) | 8 (15.7) |
| Adenocarcinoma (%) | 28 (58.3) | 29 (56.5) |
| Undifferentied (%) | 9 (18.8) | 14 (27.5) |
| Charlson (mean±CI) | 0.521±0.825 | 0.353±0.770 |
| Charlson score | ||
| 0 (%) | 29 (60.4) | 38 (74.5) |
| 1–2 (%) | 17 (35.4) | 11 (21.6) |
| >2 (%) | 2 (4.2) | 2 (4) |
| Comorbidities (mean) age+Charlson (range) | 3.15 (2–4) | 3.12 (2–4) |
| Simplified Charlson score (mean) | 3.44±4.04 | 3.12±3.66 |
Abbreviations: CI=confidence interval; DG=docetaxel and gemcitabine.